

ARRHYTHMIA DETECTION REIMAGINED as TGA approves Vigo Heart ECG patch¹



Guardian Medical Solutions is pleased to announce the TGA approval for the Vigo Heart electrocardiograph (ECG) patch (ARTGI 404983) which can assist clinicians to detect more arrhythmias²

Cardiac arrhythmias are associated with significant morbidity and mortality. With increasing numbers of cardiac patients, with the aging population and the much improved survival of patients with heart conditions, the health burden of arrhythmias will continue to rise. For example, sudden cardiac death (SCD) accounts for 15-20% of all deaths,³ and 16% of all strokes are associated with atrial fibrillation.⁴ Studies show that extended long-term ECG monitoring detects more arrhythmias when compared to intermittent monitoring.⁵

The Vigo Heart patch Holter, is a continuous cardiac rhythm monitoring and reporting solution designed to optimise patient and clinician convenience and supplement clinical diagnosis. Wireless, showerproof and ergonomically designed, the compact patch ensures user compliance and hindrance free monitoring with reporting 96.7% accuracy of arrhythmia detection.² This is much superior to existing Holter systems used currently. This is the second patch supported by the Vigo platform which is agnostic for devices. This platform flexibility allows for technology to be readily adopted and delivered as a service.

In the Vigo system, the data recorded is triple checked by cloud engineering and AI algorithms to detect cardiac rhythm abnormalities. Each ECG analysis is verified by two Certified Cardiac Technicians (CCT), with any indeterminant findings escalated to the medical director, before reports are released to Cardiology Specialists. Quality assurance programs continuously underline data integrity, processing and outputs.

The Vigo Heart solution as a superior option for clinicians to detect more arrhythmias seamlessly through improved monitoring technology and substantially improved patient compliance and experience, compared with conventional Holter systems.

The Vigo Heart solution was developed and is utilised in clinical practice in India with over 10,000 patient tests performed. This has established a solid knowledge platform of patient and clinician user experience, on which to enter the Australia market to improve on cardiology arrythmia detection.

Guardian Medical Solutions is continuing the commercialisation process of the Vigo Heart ECG patch for use in Australia.

References

- 1. Australian Register of Therapeutic Goods (ARTG) approved February 2023
- 2. Fiorina L, Maupain C, Cardella C et al Evaluation of an Ambulatory ECG Analysis Platform Using Deep Neural Networks in Routine Clinical Practice. Journal of American Heart Association 2022; 11 (18):0261956
- Hayashi M, Shimizu W, Albert C M. The Spectrum of Epidemiology Underlying Sudden Cardiac Death. Circ Res. 2015 Jun 5;116(12):1887-906.
- 4. Australian Institute of Health and Welfare https://aihw.gov.au/reports/heart-stroke-vasculardiseases/atrial-fibrillation-in-australia/contents/stroke-and-atrial-fibrillation

 Fredrikson T, Gudmundsdottir K K, Frykman V et al. Intermittent vs continuous electrocardiogram event recording for detection of atrial fibrillation-Compliance and ease of use in an ambulatory elderly population. Clinical Cardiology. 2020 Apr;43(4):355-362. <u>https://doi.org/10.1002/clc.23323</u>

Company Biography

Guardian Medical Solutions is an Australian Biotechnology company that integrates patient monitoring devices with leading edge technology modalities to enable optimised data collection, recording and detection reporting.

Contact Information

info@guardianmedicalsolutions.com

28 February 2023